Amiodarone Hydrochloride Injection, Solution
Product Images NDC 51662-1205

This is a description of a medication called Amiodarone Hydrochloride Injection, intended for intravenous use only, with a concentration of 150 mg/3 mL (50 my/mL). The medication comes in a 3L single dose vial which must be diluted before use. The package insert should be consulted for the usual dosage. It should be stored at a temperature of 20° to 25°C (68° to 77°F) according to USP standards and kept in its carton until the time of use. The manufacturer is Hikwa Farmageutica based in Portugal, and the medication is distributed in the USA by West-Ward Pharmaceutical Corp. The lot number and expiration date are not provided.*

The text provides the details of Amiodarone Hydrochloride Injection, which comes in 150mg/3mL (50mg/mL) vial. It has an NDC number of 51662-1205-2 and a LOT number of ABCDEFGHIJKLMNOPQRST, with an expiration date of 2021-06-01. The injection is meant for intravenous use only and requires dilution before use. It should be stored at 20 to 25°C (68 to 77°F), protected from light and excessive heat. The manufacturer's package insert should be consulted for more information. The original manufacturer's NDC is 0143-9875-01. This product is only available on prescription, and it is distributed by HF Acquisition Co., LLC in Mukilteo, WA 98275.*

This appears to be a product identifier code that includes a unique serial number, manufacturing and distribution dates, and a reference to a manufacturer's package insert. The code is likely associated with a physical product, however, the actual product and its purpose cannot be determined from the given text.*

Amiodarone Hydrochloride Injection is a medication that is available in a 150mg/3mL (50mg/mL) vial, packaged in a box of 25. The National Drug Code (NDC) for the product is 51662-1205-3, and the lot number is ABCDEFGHIJKLMNOPQRST, with an expiry date of June 1, 2021. The medication is for intravenous use only and must be diluted before use. It should be stored at a temperature between 20 and 25 degrees Celsius (68 to 77 degrees Fahrenheit) and protected from light and excessive heat until being used. The medication's package should be used for protection from light until the time of use. The manufacturer's package insert should be observed, and the original manufacturer's NDC is 0143-9875-01. The medication is only available on prescription and is distributed by HF Acquisition Co, LLC in Mukilteo, WA 98275.*

This is a summary table of adverse effects observed in different studies. The studies were either controlled or open-label, and they involved a total of 1,836 participants. The table reports the frequency of adverse effects by system. The adverse effects listed under the "Body as a whole" category are fever. Under the "Cardiovascular System" category, the adverse effects listed are bradycardia, congestive heart failure, heart arrest, hypotension, and ventricular tachycardia. Under the "Digestive System," the adverse effects listed are abnormal liver function tests and nausea.*

This text provides instructions for administering amiodarone in three stages for treating conditions like cardiac arrhythmia. During the first stage, 150 mg of the infusion is recommended to be administered within the first ten minutes, after which a dose of 360 mg over six hours is recommended. The final maintenance stage requires infusing 540 mg over the remaining 18 hours. The instructions specify the amount of amiodarone and D5W to be infused during each stage.*

This text appears to be a table showing the compatibility of amiodarone with different solutions and container materials at different concentrations and temperatures.*

The text is providing information about the duration of Amiodarone infusion and the initial daily dose of oral Amiodarone. The table mentions the recommended dosage for different durations. For the duration of fewer than one week, the dosage is between 800-1600 mg, for 1-3 weeks, the dosage is between 600-800 mg, and for more than three weeks, it is 400mg.*